Mesenchymal stromal cells have emerged as potential candidates for cell-based therapies
to modulate the immune response in organ transplantation and repair tissues after acute or
chronic injury. Preclinical studies have shown convincingly in rodent models that
mesenchymal stromal cells can prolong solid organ graft survival and that they can induce
immune tolerance, accelerate recovery from AKI, and promote functional improvement in
chronic nephropathies. Multiple complex properties of the cells, including …